Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Consensus Recommendation of “Hold” from Brokerages

Zealand Pharma A/S (OTCMKTS:ZLDPF) has earned a consensus rating of “Hold” from the ten research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation, one has issued a buy recommendation and one has given a strong buy recommendation to the company.

A number of equities research analysts recently weighed in on the stock. Jefferies Financial Group lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Zacks Research lowered shares of Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 13th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Berenberg Bank downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th. Finally, Wolfe Research lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th.

Zealand Pharma A/S Price Performance

Shares of ZLDPF opened at $49.28 on Monday. The firm has a fifty day moving average price of $46.90 and a 200-day moving average price of $48.19. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $3.53 billion, a P/E ratio of 8.17 and a beta of 0.88. Zealand Pharma A/S has a 12-month low of $35.93 and a 12-month high of $83.12.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.